(Q89578157)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

title

TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Kyung Hun Lee

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Yung-Jue Bang

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

3

Seock-Ah Im

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

author name string

Ahrum Min

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Hyemin Jang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Yu Jin Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Hee-Jun Kim

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Tae-Yong Kim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Keun Wook Lee

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Do-Youn Oh

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Jee-Hyun Kim

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

publication date

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

6 April 2020

copyright license

start time

3 February 2020

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants

1 reference

12 December 2020

Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions

1 reference

12 December 2020

Cytotoxicity and DNA Topoisomerase Inhibitory Activity of Benz[f]indole-4,9-dione Analogs

1 reference

12 December 2020

TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II

1 reference

12 December 2020

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

1 reference

12 December 2020

Repair of topoisomerase I-mediated DNA damage

1 reference

12 December 2020

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

1 reference

12 December 2020

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

12 December 2020

Biology of SNU cell lines

1 reference

12 December 2020

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan

1 reference

12 December 2020

DNA topoisomerases and their poisoning by anticancer and antibacterial drugs

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

12 December 2020

Cellular strategies for regulating DNA supercoiling: a single-molecule perspective

1 reference

12 December 2020

DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor

1 reference

12 December 2020

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

1 reference

12 December 2020

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

12 December 2020

Germline RAD51C mutations in ovarian cancer susceptibility

1 reference

12 December 2020

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

1 reference

12 December 2020

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

1 reference

12 December 2020

Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor

1 reference

12 December 2020

RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib

1 reference

12 December 2020

Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer

1 reference

12 December 2020

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

1 reference

12 December 2020

The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.

1 reference

12 December 2020

Comprehensive molecular characterization of gastric adenocarcinoma

1 reference

12 December 2020

Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan

1 reference

12 December 2020

A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination

1 reference

12 December 2020

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer

1 reference

12 December 2020

Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer

1 reference

12 December 2020

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines

1 reference

12 December 2020

Interplay between Fanconi anemia and homologous recombination pathways in genome integrity

1 reference

12 December 2020

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

1 reference

12 December 2020

Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.

1 reference

12 December 2020

Targeting Topoisomerase I in the Era of Precision Medicine

1 reference

12 December 2020

Identifiers

DOI

10.3390/CANCERS12020334

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32028591%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

PubMed publication ID

32028591

1 reference